Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
Pipeline News and Updates
Picture

Update for February 23, 2022

2/23/2022

 
Regulatory Update
 
The FDA approved mitapivat (Pyrukynd, Agios Pharmaceuticals), on 2/17/2022, for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency.
 
The FDA’s Peripheral and Central Nervous System Drugs Advisory Committee will meet on 3/30/2022 to review AMX0035 for the treatment of ALS.
 
Announced Research Updates
 
Cytokinetics announced that in the 20-week, 276 patient, Phase II METEORIC-HF trial, treatment with omecamtiv mecarbi did not improve peak oxygen uptake during cardiopulmonary exercise testing compared to placebo in patients with HFrEF.
 
Sage and Biogen announced that in the 15-day, 440 patient, Phase III, CORAL trial, adding zuranolone to open-label standard of care antidepressant (ADT) resulted in an 8.9 point decrease in the HAMD-17 total score at day 3 compared to a 7 point decrease with ADT alone in patients with major depressive disorder. However, the difference between zuranolone and placebo was no longer significant by day 15.
 
BMS announced that in the 16-week, 100 patient, Phase III, VALOR-HCM trial, fewer patients treated with mavacamten elected to undergo septal reduction therapy compared to placebo in patients with symptomatic obstructive hypertrophic cardiomyopathy.
 
Gilead announced that patients who completed the 14-day blinded portion of the CAPELLA trial were enrolled in an open-label extension where they received lenacapavir subcutaneously every six months and an optimized background regimen. After 52 weeks, 83% (30/36) achieved an undetectable viral load (< 50 copies/mL).
 
GSK paused enrollment in three trials of its RSV vaccine candidate in pregnant patients, at the recommendation of the Independent Data Monitoring Committee, based on an observation from a routine safety assessment.
 
Published Research Updates
 
In the 92 patient, Phase III, REALITY trial, patients treated with apatinib achieved progression-free survival of 22.2 months compared to 4.5 months with placebo in Chinese patients with radioactive iodine–refractory differentiated thyroid cancer. A Phase II trial in adults 60 and older is not affected.
 
Check out our new lower subscription rates and don't miss out on these clinical updates.

Comments are closed.
    Stay informed, subscribe to the 
    ​
    Prescribe Right Pharmaceutical Pipeline Tracker
    Latest Tweets from Prescribe Right

    Archives

    January 2023
    December 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    August 2015

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.